Needham & Company LLC reissued their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a $26.00 price target on the stock.
A number of other research firms also recently commented on PHAT. Stifel Nicolaus assumed coverage on Phathom Pharmaceuticals in a report on Friday, May 3rd. They issued a buy rating and a $24.00 price objective on the stock. HC Wainwright restated a buy rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday, May 10th.
View Our Latest Stock Analysis on PHAT
Phathom Pharmaceuticals Stock Down 1.0 %
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.43) by $0.01. The business had revenue of $1.91 million during the quarter, compared to analyst estimates of $2.76 million. On average, equities analysts expect that Phathom Pharmaceuticals will post -5.57 EPS for the current fiscal year.
Insider Activity at Phathom Pharmaceuticals
In related news, CFO Molly Henderson sold 3,435 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $11.10, for a total transaction of $38,128.50. Following the sale, the chief financial officer now directly owns 95,263 shares in the company, valued at approximately $1,057,419.30. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 24.10% of the company’s stock.
Institutional Investors Weigh In On Phathom Pharmaceuticals
Hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its stake in Phathom Pharmaceuticals by 355.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,626 shares of the company’s stock valued at $60,000 after purchasing an additional 5,171 shares in the last quarter. DAVENPORT & Co LLC acquired a new stake in Phathom Pharmaceuticals during the 4th quarter valued at approximately $91,000. Public Employees Retirement System of Ohio acquired a new stake in Phathom Pharmaceuticals during the 3rd quarter valued at approximately $92,000. Klingman & Associates LLC acquired a new stake in Phathom Pharmaceuticals during the 1st quarter valued at approximately $110,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in Phathom Pharmaceuticals during the 1st quarter valued at approximately $119,000. Institutional investors and hedge funds own 99.01% of the company’s stock.
Phathom Pharmaceuticals Company Profile
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Read More
- Five stocks we like better than Phathom Pharmaceuticals
- Top Stocks Investing in 5G Technology
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Best Stocks Under $10.00
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- How to Invest in the Best Canadian StocksĀ
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.